2026 ICD-10-CM Diagnosis Code T48.3X5AAdverse effect of antitussives, initial encounter

ICD-10-CM CodesS00–T88T36-T50T48

ICD-10-CM T48.3X5A
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

T48.3X5A is a billable ICD-10-CM diagnosis code for adverse effect of antitussives, initial encounter. The 7th character A marks it as an initial encounter code, used while the patient is receiving active treatment. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 917 through 918. The code is not accepted as a principal diagnosis by the Medicare Code Editor. Coders also document this condition as adverse reaction to pipazethate. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Adverse effects of drugs and medicaments, initial encounter.

Code Identity

ICD-10-CM Code
T48.3X5A
Billable Status
Yes — Valid for Submission
Code Describes
Adverse effect of antitussives, initial encounter
Short Description
Adverse effect of antitussives, initial encounter
Same as the full description in the CMS dataset.
Parent Code
Adverse effect of antitussives

Code Classification

ChapterS00–T88Injury, poisoning and certain other consequences of external causes
SectionT36-T50Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
CategoryT48Poisoning by, adverse effect of and underdosing of agents primarily acting on smooth and skeletal muscles and the respiratory system
This CodeT48.3X5AAdverse effect of antitussives, initial encounter

Code EditsBilling

Medicare Code Editor checks that affect claim validity for T48.3X5A.

There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Adverse reaction to pipazethate
  • Cough suppressant adverse reaction
  • Dextromethorphan hydrobromide adverse reaction
  • Isoaminile adverse reaction
  • Noscapine adverse reaction
  • Pholcodine adverse reaction

Coding GuidelinesGuidance

When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of agents primarily acting on smooth and skeletal muscles and the respiratory system (T48). Use the following options for the applicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR INJ028
Adverse effects of drugs and medicaments, initial encounter
Default principal diagnosis: inpatient No · outpatient Yes

Clinical InformationClinical

  • Dextromethorphan

    methyl analog of dextrorphan that shows high affinity binding to several regions of the brain, including the medullary cough center. this compound is an nmda receptor antagonist (receptors, n-methyl-d-aspartate) and acts as a non-competitive channel blocker. it is one of the widely used antitussives, and is also used to study the involvement of glutamate receptors in neurotoxicity.
  • Noscapine

    a naturally occurring opium alkaloid that is a centrally acting antitussive agent.

Table of Drugs and ChemicalsClinical

Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.

SubstanceAccidentalSelf-harmAssaultUndeter­minedAdverse
Effect
Under­dosing
Antitussive NECT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
Antitussive NEC::codeine mixtureT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
Antitussive NEC::opiateT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
BenproperineT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
BenzonatateT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
Bibenzonium bromideT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
ButamirateT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
CarbetapentaneT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
ChlophedianolT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
ClobutinolT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
ClofedanolT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
CloperastineT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
ClophedianolT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
DextromethorphanT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
Dibunate sodiumT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
DimemorfanT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
DimethoxanateT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
DropropizineT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
FedrilateT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
FominobenT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
Isoaminile (citrate)T48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
LevdropropizineT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
MethorateT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
NarcotineT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
NectadonT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
NoscapineT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
Oxeladin (citrate)T48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
OxolamineT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
PentoxyverineT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
PholcodineT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
PicoperineT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
PipazetateT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
PiperidioneT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
PrenoxdiazineT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
RomilarT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
TessalonT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
ThebaconT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
TipepidineT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6
ZipeprolT48.3X1T48.3X2T48.3X3T48.3X4T48.3X5T48.3X6

Patient EducationClinical

Drug Reactions

Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.

The full article covers:

  • What is a drug interaction?
  • What are side effects?
  • What are drug allergies?
  • How can I stay safe when taking medicines?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert T48.3X5A to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
995.29 Adv eff med/biol NEC/NOS
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.
ICD-9-CM
E945.4 Adv eff antitussives
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About T48.3X5AOverview

Is T48.3X5A (Adverse effect of antitussives) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of antitussives, initial encounter on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What does the 7th character A in T48.3X5A mean?

The final character A marks the initial encounter: use it while the patient is receiving active treatment for adverse effect of antitussives, such as an emergency visit or first evaluation.

What MS-DRG does T48.3X5A group to?

On inpatient claims, adverse effect of antitussives, initial encounter maps to MS-DRG 917, 918, with relative weights from 0.8571 to 1.5684 depending on complications. Higher weights mean higher Medicare reimbursement.

Can T48.3X5A be a principal diagnosis?

No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of antitussives, initial encounter describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.

What is the ICD-9 equivalent of T48.3X5A?

Under the General Equivalence Mappings, adverse effect of antitussives, initial encounter converts to ICD-9-CM 995.29 (adv eff med/biol NEC/NOS) and E945.4 (adv eff antitussives). The mapping is approximate, so confirm the match fits the documentation.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.